Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.38

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned an average recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $6.38.

TSHA has been the subject of a number of research reports. Needham & Company LLC decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group lowered their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $1.50 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22. The stock has a market capitalization of $307.41 million, a price-to-earnings ratio of -7.38 and a beta of 0.44. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The company’s 50-day simple moving average is $1.99 and its 200-day simple moving average is $2.40.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. During the same quarter last year, the firm earned ($0.38) EPS. Equities analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP raised its holdings in shares of Taysha Gene Therapies by 64.7% during the third quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock valued at $469,000 after buying an additional 91,755 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Taysha Gene Therapies during the 3rd quarter valued at $416,000. Privium Fund Management B.V. boosted its position in Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after acquiring an additional 21,500 shares during the period. Quantum Private Wealth LLC grew its stake in shares of Taysha Gene Therapies by 5.1% in the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the period. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.